
Lilly Reports First-Quarter 2025 Financial Results And Highlights Pipeline Momentum
(MENAFN- PR Newswire) Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound. Pipeline progress included positive Phase 3 trial results for orforglipron (small molecule oral GLP-1 agonist) in Type 2 diabetes …